BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16544143)

  • 1. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
    Felici A; Loos WJ; Verweij J; Cirillo I; de Bruijn P; Nooter K; Mathijssen RH; de Jonge MJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):673-80. PubMed ID: 16544143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
    Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
    Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.
    Kim H; Park JH; Bang SJ; Kim DH; Cho HR; Kim GY; Min YJ
    Jpn J Clin Oncol; 2005 Dec; 35(12):727-32. PubMed ID: 16332720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Mikami Y; Tanigaki Y; Katori H; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Sakuma Y; Aikoh K
    Int J Clin Oncol; 2004 Jun; 9(3):161-6. PubMed ID: 15221599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
    Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
    Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
    Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
    Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
    Bae WK; Hwang JE; Shim HJ; Cho SH; Lee JK; Lim SC; Chung WK; Chung IJ
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):589-95. PubMed ID: 19830427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of docetaxel, Cisplatin, 5-Fluorouracil and leucovorin.
    Mulcahy MF; Loehrer PJ; Meropol NJ; Rademaker AW; Benson Iii AB
    Oncology; 2005; 68(4-6):479-84. PubMed ID: 16020978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
    Takahashi I; Emi Y; Kakeji Y; Tokunaga E; Ushiro S; Oki E; Watanabe M; Baba H; Maehara Y
    Oncol Rep; 2006 Apr; 15(4):849-54. PubMed ID: 16525670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
    Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
    Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
    Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.